Ropes & Gray represented Viridian Therapeutics in an exclusive licensing and collaboration deal with Kissei Pharmaceutical to develop and market thyroid eye disease therapy veligrotug and VRDN-003 in Japan. The transaction was announced on July 30.
Under the agreement, Viridian will receive a $70 million upfront payment with potential to receive an additional $315 million in milestone payments as well as tiered royalties on net sales in Japan.
The Ropes & Gray team was led by life sciences licensing partner Hannah England and life sciences licensing associates Nicole Rohr and Ryan Kramer and included tax partner David Saltzman.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
